切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2018, Vol. 12 ›› Issue (04) : 386 -391. doi: 10.3877/cma.j.issn.1674-1358.2018.04.014

所属专题： 文献；

论著

乙型肝炎病毒表面抗原定量检测对恩替卡韦停药后乙型肝炎复发的预测价值
王昌生1,†(), 岳晓荷1, 路淼2   
  1. 1. 5726002　东方市，海南省东方市东方医院检验科
    2. 570100　海口市，海南金域医学检验中心
  • 收稿日期:2018-02-01 出版日期:2018-08-15
  • 通信作者: 王昌生
  • 基金资助:
    海南医学院科研基金资助项目(No. 0020015128)

Predictive value of quantitative detection of hepatitis B virus surface antigen in the relapse of hepatitis B induced by entecavir

Changsheng Wang1,†(), XiaoHe Yue1, Miao Lu2   

  1. 1. Clinical Lab, East Hospital of Dongfang City, Hainan 572600, China
    2. Jinyu Medical Examination Center of Hainan, Haikou 570100, China
  • Received:2018-02-01 Published:2018-08-15
  • Corresponding author: Changsheng Wang
  • About author:
    Corresponding author: Wang Changsheng, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王昌生, 岳晓荷, 路淼. 乙型肝炎病毒表面抗原定量检测对恩替卡韦停药后乙型肝炎复发的预测价值[J/OL]. 中华实验和临床感染病杂志(电子版), 2018, 12(04): 386-391.

Changsheng Wang, XiaoHe Yue, Miao Lu. Predictive value of quantitative detection of hepatitis B virus surface antigen in the relapse of hepatitis B induced by entecavir[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(04): 386-391.

目的

评价乙型肝炎病毒表面抗原（HBsAg）定量检测对恩替卡韦停药后复发乙型肝炎的诊断效能。

方法

回顾性分析2013年1月至2016年1月于海南省东方市东方医院应用恩替卡韦抗病毒治疗达到停药指征的80例慢性乙型肝炎（CHB）患者的临床资料，根据两年内是否发生病毒学复发，分为复发组（60例）和未复发组（20例），比较两组患者停药后的病毒学指标（HBV DNA载量、HBeAg转阴率和HBsAg定量等），应用Cox回归模型探究患者复发的影响因素，以ROC曲线评价治疗后HBsAg定量检测在预测恩替卡韦停药后病情复发中的价值。

结果

入组患者于24个月随访中共发生病毒学复发60例（75.00%），中位复发时间为9.5（5～24）个月。复发组和未复发组患者的年龄、性别比例、体质指数、乙型肝炎病史和甲胎蛋白等临床资料差异无统计学意义（t = 0.854、χ2 = 1.077、t= 0.749、t = 1.354、t = 1.499，P= 0.396、0.299、0.456、0.180、0.138）。复发组患者的HBeAg阳性率、肝硬化、乙型肝炎家族史、治疗前HBV DNA载量、治疗后HBsAg定量和HBsAg阳性率均显著高于未复发组（χ2= 4.364、6.667、4.689，t= 4.096、2.040、8.219、5.760，P= 0.037、0.010、0.030、0.043，< 0.001，0.016），而用药时间显著低于未复发组（t= 2.006、P= 0.048），差异均有统计学意义。多因素Cox回归分析显示，肝硬化（HR= 1.587、P= 0.041）、HBeAg阳性（HR= 1.742、P = 0.044）和治疗后HBsAg定量（HR= 2.606、P= 0.008）均为影响恩替卡韦停药后复发的独立危险因素。ROC曲线显示应用HBsAg定量（AUC= 0.902，P < 0.001）预测恩替卡韦停药后复发的曲线下面积高于半定量检测（AUC= 0.650、P= 0.046），HBsAg定量最佳截点为2.03 log10IU/ml，准确率、灵敏度、特异度、阳性预测值和阴性预测值分别为91.25%、91.67%、90.00%、96.49%和78.26%。

结论

肝硬化、HBeAg阳性和HBsAg高水平均为恩替卡韦停药后复发的独立危险因素，应用HBsAg定量检测预测恩替卡韦停药后乙型肝炎复发具有较高的诊断效能。

关键词: 肝炎，乙型，慢性, 恩替卡韦, 表面抗原，肝炎病毒，乙型, 复发
Objective

To investigate the diagnostic efficacy of quantitative detection of hepatitis B virus surface antigen (HBsAg) in patients with hepatitis B relapse after entecavir withdrawal.

Methods

Total of 80 patients with chronic hepatitis B (CHB) who received antiviral treatment with entecavir in Dongfang Hospital of Hainan Province from January 2013 to January 2016 were analyzed, retrospectively. The patients were divided into recurrence group (60 cases) and non-recurrence group (20 cases). The virological indexes including HBV DNA load and HBsAg determination were compared between the two groups. The influencing factors of relapse after entecavir treatment were analyzed by Cox regression model. The value of quantitative HBsAg detection after treatment in predicting the recurrence of patients with entecavir treatment was evaluated by ROC curve.

Results

A total of 60 cases (75.00%) had virological recurrence during the 24-month follow-up, with the median recurrence time of 9.5 (5-24) months. There was no significant difference in age, sex ratio, body mass index, history of CHB and AFP between recurrent group and non-recurrence group (t= 0.854,χ2= 1.077,t = 0.749,t= 1.354,t= 1.499;P= 0.396, 0.299, 0.456, 0.180, 0.138). The positive rate of HBeAg, cirrhosis, family history of hepatitis B, HBV DNA load before treatment, HBsAg quantification after treatment and HBsAg positive rate in recurrence group were significantly higher than those in the non-recurrence group (χ2= 4.364, 6.667, 4.689,t= 4.096, 2.040, 8.219, 5.760;P= 0.037, 0.010, 0.030, 0.043,< 0.001, 0.016), but the medication time was significantly lower than that of non-recurrence group (t= 2.006,P= 0.048), with significant differences. Multivariate Cox regression analysis showed that cirrhosis (HR= 1.587,P= 0.041), HBeAg positive (HR= 1.742,P= 0.044) and HBsAg quantitative (HR= 2.606,P= 0.008) were independent risk factors for the relapse after entecavir treatment. ROC curve showed that the area under the curve of HBsAg quantification (AUC= 0.902,P< 0.001) was higher than that of semi-quantitative detection (AUC= 0.650,P = 0.046), with significant differences. The best cut-off point of HBsAg quantification was 2.03 log10IU/ml. The accuracy, sensitivity, specificity, positive predictive value and negative predictive value were 91.25%, 91.67%, 90%, 96.49% and 78.26%, respectively.

Conclusions

Liver cirrhosis, HBeAg positive and high HBsAg levels after treatment are independent risk factors for the relapse of hepatitis B after entecavir withdrawal. The quantitative detection of HBsAg for predicting the recurrence of patients with entecavir withdrawal had a high diagnostic efficacy.

Key words: Chronic hepatitis B, Entecavir, Hepatitis B surface antigen, Relapse
图1 CHB患者ETV停药后的病毒学复发和临床复发率
表1 复发组和未复发组患者的临床资料
临床资料 复发组（60例） 未复发组（20例） 统计量 P值
年龄（±s，岁） 43.6 ± 6.3 45.0 ± 6.7 t= 0.854 0.396
性别[例（%）] ? ? χ2= 1.077 0.299
? 男性 35（58.3） 9（45.0） ? ?
? 女性 25（41.7） 11（55.0）
BMI（±s，kg/m2） 23.1 ± 2.7 23.6 ± 2.2 t= 0.749 0.456
治疗前HBeAg定性[例（%）] ? ? χ2= 4.364 0.037
? 阳性 40（66.7） 10（50.0） ? ?
? 阴性 20（33.3） 10（50.0）
用药时间（±s，年） 1.8 ± 0.4 2.0 ± 0.4 t= 2.006 0.048
乙型肝炎病史（±s，年） 4.2 ± 2.4 3.3 ± 2.3 t= 1.354 0.180
肝硬化[例（%）] 25（41.7） 3（15.0） χ2= 4.689 0.030
乙型肝炎家族史[例（%）] 20（33.3） 2（10.0） χ2= 4.096 0.043
治疗前HBV DNA载量（±s，log10IU/ml） 7.1 ± 1.6 6.2 ± 1.5 t= 2.040 0.045
治疗后HBsAg定量（±s，log10IU/ml） 2.9 ± 0.6 1.9 ± 0.4 t= 8.219 < 0.001
? 治疗后HBsAg定性[例（%）] ? ? χ2= 5.760 0.016
? 阳性 27（45.0） 3（15.0） ? ?
? 阴性 33（55.0） 17（85.0）
甲胎蛋白（±s，μg/L） 46.7 ± 7.2 44.1 ± 5.6 t= 1.499 0.138
表2 影响恩替卡韦停药后病情复发的多因素Cox回归分析
变量 B值 标准误差 Wald值 P值 HR值 95%CI
肝硬化 0.581 0.557 3.653 0.041 1.587 1.112～3.766
HBeAg阳性 0.632 0.622 3.502 0.044 1.742 1.096～4.662
治疗后HBsAg 1.018 0.326 6.298 0.008 2.606 1.278～5.911
图2 HBsAg定量与半定量预测恩替卡韦停药后复发的ROC曲线
[1]
科技部十二五重大专项联合课题组专家. 乙型肝炎病毒相关肝硬化的临床诊断,评估和抗病毒治疗的综合管理[J]. 中华肝脏病杂志,2014,22(5):327-335.
[2]
McMahon BJ. Chronic hepatitis B virus infection[J]. Med Clin North Am,2014,98(1):39-54.
[3]
慢性乙型肝炎核苷(酸)类似物经治患者抗病毒治疗专家委员会. 慢性乙型肝炎核苷(酸)类似物经治患者抗病毒治疗专家共识: 2016年更新[J]. 中国肝脏病杂志(电子版),2016,8(3):15-20.
[4]
Martinot-Peignoux M,Lapalus M,Asselah T,Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome[J]. Liver Int,2014,34(S1):S97-S107.
[5]
Martinot-Peignoux M,Asselah T,Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients[J]. Liver Int,2015,35(S1):82-90.
[6]
中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 中华肝脏病杂志,2011,19(1):13-24.
[7]
慢性乙型肝炎核苷(酸)类药物经治患者抗病毒治疗专家委员会. 慢性乙型肝炎核苷(酸)类药物经治患者抗病毒治疗专家共识[J]. 中华医学信息导报,2014,29(1):122-126.
[8]
抗乙型肝炎病毒核苷酸类似物不良反应管理专家委员会. 抗乙型肝炎病毒核苷(酸)类似物不良反应管理专家共识[J/CD]. 中华实验和临床感染病杂志(电子版),2016,10(5):522-526.
[9]
张国民,孙校金,王富珍, 等. 中国18-59岁人群乙型病毒性肝炎流行病学特征分析及乙型肝炎疫苗免疫策略探讨[J]. 中国疫苗和免疫,2013,19(3):266-270.
[10]
Tsai MC,Chen CH,Hu TH, et al. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs[J]. J Formos Med Assoc,2017,116(7):512-521.
[11]
Jang JW,Choi JY,Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis[J]. Hepatology,2015,61(6):1809-1820.
[12]
Ridruejo E,Marciano S,Galdame O, et al. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir[J]. J Viral Hepat,2014,21(8):590-596.
[13]
Fung J,Wong T,Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years[J]. Hepatology,2017,66(4):1036-1044.
[14]
Ahn J,Lee HM,Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US--the ENUMERATE study[J]. Aliment Pharmacol Ther,2016,43(1):134-144.
[15]
史萍,蒋龙凤,李军. 慢性乙型肝炎患者核苷(酸)类药物停药后复发的相关因素荟萃分析[J]. 中华临床感染病杂志,2015,8(1):58-69.
[16]
Lee HA,Seo YS,Park SW, et al. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B[J]. Clin Mol Hepatol,2016,22(3):382-389.
[17]
Shinkai N,Kusumoto S,Murakami S, et al. Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay[J]. Liver Int,2017,37(8):1138-1147.
[18]
Wang CC,Tseng KC,Hsieh TY, et al. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg[J]. Am J Gastroenterol,2016,111(9):1286-1294.
[19]
Ji M,Hu K. Recent advances in the study of hepatitis B virus covalently closed circular DNA[J]. Virol Sin,2017,32(6):454-464.
[20]
Gao Y,Li Y,Meng Q, et al. Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?[J]. J Clin Microbiol,2017,55(10):2972-2982.
[21]
Sonneveld MJ,Rijckborst V,Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology,2012,56(1):67-75.
[22]
Kim SH. ELISA for Quantitative determination of hepatitis B virus surface antigen[J]. Immune Netw,2017,17(6):451-459.
[23]
游春芳,周利民,邓薇. 基因1b型慢性丙型肝炎患者血清铁蛋白水平与聚乙二醇干扰素抗病毒疗效的关系[J]. 临床肝胆病杂志,2017,33(9):1713-1716.
[24]
Sonneveld MJ,Rijckborst V,Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J]. Hepatology,2010,52(4):1251-1257.
[25]
Zhang L,Xie XY,Chen Y, et al. Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads[J]. Medicine (Baltimore),2017,96(52):e9377.
[1] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[2] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[3] 谢田伟, 庞于樊, 吴丽. 超声引导下不同消融术对甲状腺良性结节体积缩减率、复发率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 80-83.
[4] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[5] 曾繁利, 齐秩凯, 杨贺庆. 两种经Glisson蒂鞘解剖路径肝切除术治疗原发性肝癌的肿瘤学疗效及风险比对[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 525-527.
[6] 高建新, 王啸飞, 于淼, 路夷平. 局部进展期直肠癌新辅助治疗后行ISR术远切缘距离的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 539-543.
[7] 丁志翔, 于鹏, 段绍斌. 血浆BRAF基因检测对腹腔镜右半结肠癌D3根治术中行幽门淋巴结清扫的指导价值[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 570-573.
[8] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[9] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[10] 周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[11] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[12] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[13] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[14] 杭丽, 张耀辉, 孙文恺. 参菝抗瘤液对结直肠腺瘤性息肉术后肠道功能、炎症指标及复发情况的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 413-416.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号